COMMUNIQUÉS West-GlobeNewswire

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
15/04/2024
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company [...]
REPEAT – MEDIA ADVISORY: Press conferences with patients who have been charged user fees of hundreds or even thousands of dollars at for-profit surgery clinics
15/04/2024
TORONTO and LONDON and WATERLOO and BRAMPTON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Patients are being threatened with extremely long wait times, denied vital procedure information, and coerced or manipulated into [...]
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
15/04/2024
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of [...]
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
15/04/2024
Richard Smith brings 25 years of expertise in building commercial excellence and partnering with the healthcare community across multiple therapeutic areas Chiesi USA remains steadfast in its preparations for the full- [...]
Extendicare Announces April 2024 Dividend of C$0.04 per Share
15/04/2024
MARKHAM, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
15/04/2024
Three batches tested and validated by third-party laboratory VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed [...]
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
15/04/2024
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in [...]
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
15/04/2024
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report becoming free from [...]
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
15/04/2024
Expects the First Quarter of 2024 will be the 4 th consec utive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expenses (SG&A [...]
Biomerica provides update on inFoods® IBS expansion
15/04/2024
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in p hysicians prescribing i nFoods more than doubled each [...]
CVRx announces availability of additional data supporting long-term benefits of Barostim
15/04/2024
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a [...]
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
15/04/2024
Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administration Reimbursement through Medicare/Medicaid represents [...]
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
15/04/2024
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients [...]
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
15/04/2024
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain [...]
Immuron to host Live Virtual Event
15/04/2024
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, [...]
Transactions in Connection with Share Buy-back Program Genmab
15/04/2024
Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
Cbio A/S, développeur de thérapies par lymphocytes T, dévoile son rapport annuel 2023, alors que ses préparatifs d’essais cliniques sont en cours, signalant ainsi un passage décisif au stade clinique grâce à un financement garanti de 40 millions DKK
15/04/2024
SØBORG, Danemark, 15 avr. 2024 (GLOBE NEWSWIRE) -- Cbio A/S, pionnière des thérapies par lymphocytes T de nouvelle génération pour les tumeurs solides, dévoile ses résultats financiers 2023 et actualités d’entreprise. [...]
BC Platforms and NTT Group Announce Official Opening Ceremony for Exclusive Collaboration and Launch of Japanese Precision Medicine Platform
15/04/2024
ZURICH, Switzerland, April 15, 2024 (GLOBE NEWSWIRE) -- BC Platforms (BCP), a global leader in real world data, healthcare data management, and analytics, today announces an exclusive collaboration with NTT Life Science [...]
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
15/04/2024
The study plans for the enrolment of 12 patients in 5 French clinical centers First study results expected in Q3 2024 This study will enable an evaluation of the intravenous administration of phages, particularly [...]

Pages